Skip to main content
BrainCited

Botulinum Neurotoxins: History, Mechanism, and Applications. A Narrative Review.

Arik Monash, Joseph Tam, Osnat Rosen, Hermona Soreq
Review Journal of neurochemistry 2025 8 次引用
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'pmid\u003D40762356'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

研究类型
Review
研究人群
None
干预措施
Botulinum Neurotoxins: History, Mechanism, and Applications. A Narrative Review. None
对照组
None
主要结局
None
效应方向
Mixed
偏倚风险
Unclear

Abstract

Botulinum neurotoxins (BoNTs), produced by Clostridium botulinum, exert their potent neuroparalytic effects by specifically targeting presynaptic cholinergic nerve terminals. BoNTs consist of a heavy chain that mediates high-affinity neuronal binding and endocytosis, and a light chain that, once translocated into the cytosol, acts as a zinc-dependent metalloprotease. The light chain cleaves SNARE proteins essential for synaptic vesicle fusion, thereby inhibiting acetylcholine release and leading to flaccid paralysis. This intoxication spans foodborne, wound, and infant botulism, all characterized by commonly observed heat-resistant endospores that enable bacterial survival under adverse conditions. BoNT intoxication induces flaccid paralysis, and both natural and synthetic neurotoxins disrupt neuronal communication by targeting synaptic components. However, BoNTs differ in their origin, mechanism of action, structure, and interactions. Clinical harnessing of non-poisoning low doses of BoNT/A and BoNT/B serotypes is used for alleviating symptoms of diverse diseases. Molecular engineering and clinical formulation enabled BoNTs optimization into pharmacologically safe and targeted therapeutic agents that replicate the selective neuronal silencing observed in their natural forms.

简要概述

Clinical harnessing of non‐poisoning low doses of BoNT/A and BoNT/B serotypes is used for alleviating symptoms of diverse diseases using pharmacologically safe and targeted therapeutic agents that replicate the selective neuronal silencing observed in their natural forms.

Used In Evidence Reviews

Similar Papers